Compare Stocks → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:JANNASDAQ:MRKRNASDAQ:PMN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.77+4.8%$0.83$0.50▼$4.67$41.99M0.74597,487 shs76,688 shsJANJanOne$4.22-1.9%$3.09$0.22▼$5.26$36.25M2.04253,441 shs45,362 shsMRKRMarker Therapeutics$4.23-0.9%$4.32$1.16▼$9.68$37.69M1.5419,566 shs11,360 shsPMNProMIS Neurosciences$1.83-4.9%$2.03$0.95▼$8.95$34.70M0.6734,720 shs4,156 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics-7.46%-3.36%-11.19%+40.95%-82.46%JANJanOne-0.46%+21.13%+70.63%+586.90%+313.46%MRKRMarker Therapeutics+6.22%+3.89%-9.34%+5.43%+177.25%PMNProMIS Neurosciences+1.24%+0.30%-19.81%-2.80%-68.86%Free report reveals “two-baggers” for 2024 (Ad)We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.Download your free report today!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.6465 of 5 stars3.41.00.04.20.91.71.3JANJanOneN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker Therapeutics4.0882 of 5 stars3.55.00.03.91.71.70.0PMNProMIS Neurosciences1.9089 of 5 stars3.54.00.00.00.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,169.37% UpsideJANJanOneN/AN/AN/AN/AMRKRMarker Therapeutics3.00Buy$11.00160.05% UpsidePMNProMIS Neurosciences3.00Buy$8.00337.16% UpsideCurrent Analyst RatingsLatest PMN, JAN, CARA, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2024MRKRMarker TherapeuticsLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$11.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M2.00N/AN/A$1.05 per share0.73JANJanOne$39.61M0.92N/AN/A($0.67) per share-6.30MRKRMarker Therapeutics$3.31M11.39N/AN/A$1.58 per share2.68PMNProMIS Neurosciences$10K3,469.86N/AN/A$0.20 per share9.15Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/13/2024 (Confirmed)JANJanOne-$7.81MN/A0.00∞N/AN/A-224.02%-63.92%8/20/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00N/AN/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)PMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)Latest PMN, JAN, CARA, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/ACARACara Therapeutics-$0.38N/A+$0.38N/AN/AN/A4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43JANJanOneN/A0.060.06MRKRMarker TherapeuticsN/A5.575.57PMNProMIS NeurosciencesN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%JANJanOne6.27%MRKRMarker Therapeutics22.39%PMNProMIS Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%JANJanOne3.00%MRKRMarker Therapeutics24.10%PMNProMIS Neurosciences10.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.67 million52.37 millionOptionableJANJanOne1998.59 million8.34 millionNot OptionableMRKRMarker Therapeutics88.91 million6.77 millionNot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionablePMN, JAN, CARA, and MRKR HeadlinesSourceHeadlineHead to Head Comparison: ProMIS Neurosciences (NASDAQ:PMN) versus Bullfrog AI (NASDAQ:BFRG)americanbankingnews.com - May 8 at 1:34 AMProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodiesglobenewswire.com - April 30 at 7:00 AMNew drug may help reduce signs of motor deterioration in Parkinson'smedicalnewstoday.com - April 26 at 4:11 AMProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93msn.com - April 17 at 9:02 AMProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSglobenewswire.com - April 9 at 7:00 AMProMIS Neurosciences to Present in Upcoming Investor Conferences in Aprilglobenewswire.com - April 4 at 7:00 AMProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlightsglobenewswire.com - April 1 at 4:15 PMProMIS Neurosciences Strengthens Global Intellectual Property Portfolioglobenewswire.com - March 11 at 7:00 AMProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 22 at 7:00 AMResearchers discover a promising compound to treat neuropathic paininterestingengineering.com - February 4 at 12:20 AMProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccinefinance.yahoo.com - January 22 at 8:48 AMProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transitionfinanznachrichten.de - January 3 at 9:13 AMBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)markets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officermarkets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences, Inc. Announces Leadership Transitionfinance.yahoo.com - January 3 at 9:13 AMProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14msn.com - November 14 at 7:10 PMProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 3:28 PMProMIS Neurosciences Inc. [PMN] Investment Appeal on the Riseknoxdaily.com - August 23 at 4:58 PMProMIS Neurosciences scales 31% on $20.4M private placementmsn.com - August 22 at 7:40 AMProMIS Neurosciences Announces $20.4 Million Private Placement Financingfinance.yahoo.com - August 21 at 4:38 PMProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlightsfinance.yahoo.com - May 15 at 6:49 PMClosing Bell: Promis Neurosciences Inc down on Friday (PMN)theglobeandmail.com - May 6 at 8:15 AMClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)theglobeandmail.com - April 27 at 10:10 PMData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Diseasefinance.yahoo.com - April 25 at 5:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.JanOneNASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.